drug discovery
with the next generation of
patient selection
unlocking unique biology
and deep learning
driving a new era of
clinical development
Building Revolutionary Tools
Proteins, not genes, are the true drivers of biology and disease. Yet, most of the pharmaceutical industry still relies on genetic data, leading to slow and costly development. Over $3B per drug, 12 years to market, and a mere 5% clinical success rate. Advances in proteomics and machine learning unlock an entirely new path for drug discovery, one driven by real biology, not assumptions.
Yatiri Bio is here to change this narrative, re-envisioning the pharmaceutical industry's current drug discovery process by integrating patient data sets with testable empirical models to guide patient selection and clinical development.
Bridging The Gap
Yatiri Bio transforms proteomic knowledge into actionable therapeutic strategy. We build advanced proteomics and bioinformatics tools to reveal the proteins driving disease and identify robust therapeutic signatures for precise patient selection. Our deep learning models integrate these insights to predict patient response and guide development decisions. This approach allows therapies to be tested with greater precision, eliminating inefficiencies and accelerating clinical success.
Our vision is to match patients with the treatments most likely to benefit them - all through rigorous, data-centric approaches.